BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 36809752)

  • 1. Neoadjuvant Chemotherapy Followed by Cytoreductive Surgery and HIPEC Improves Survival in Peritoneal Metastatic Gastric Cancer.
    Akturk Esen S; Ozgun YM; Hasturk D; Ucar G; Bostanci EB; Sendur MAN; Uncu D
    Oncology; 2023; 101(5):321-327. PubMed ID: 36809752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy.
    Zhou S; Jiang Y; Liang J; Pei W; Zhou Z
    World J Surg Oncol; 2021 May; 19(1):151. PubMed ID: 34001125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study.
    Yu P; Ye Z; Dai G; Zhang Y; Huang L; Du Y; Cheng X
    BMC Cancer; 2020 Nov; 20(1):1108. PubMed ID: 33198674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIPEC and CRS in peritoneal metastatic gastric cancer - who really benefits?
    Hotopp T
    Surg Oncol; 2019 Mar; 28():159-166. PubMed ID: 30851894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 6. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
    Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
    J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis: A 30-year Institutional Experience.
    Valenzuela CD; Levine EA; Mangieri CW; Gawdi R; Moaven O; Russell G; Lundy ME; Perry KC; Votanopoulos KI; Shen P
    Ann Surg Oncol; 2022 Jun; 29(6):3436-3445. PubMed ID: 35286531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged hyperthermic intraperitoneal chemotherapy duration with 90 minutes cisplatin might increase overall survival in gastric cancer patients with peritoneal metastases.
    Steinhoff H; Acs M; Blaj S; Dank M; Herold M; Herold Z; Herzberg J; Sanchez-Velazquez P; Strate T; Szasz AM; Piso P
    World J Gastroenterol; 2023 May; 29(18):2850-2863. PubMed ID: 37274066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still beneficial in patients diagnosed with colorectal peritoneal metastasis who underwent palliative chemotherapy?
    Cho HJ; Kim JW; Kim WR
    Asian J Surg; 2024 Jan; 47(1):296-302. PubMed ID: 37648541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastric cancer with peritoneal metastases: a single center outline and comparison of different surgical and intraperitoneal treatments.
    Santullo F; Ferracci F; Abatini C; Halabieh MAE; Lodoli C; D'Annibale G; Di Cesare L; D'Agostino L; Pecere S; Di Giorgio A; Strippoli A; Pacelli F
    Langenbecks Arch Surg; 2023 Nov; 408(1):437. PubMed ID: 37973620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups.
    Gomes David M; Bakrin N; Salleron J; Kaminsky MC; Bereder JM; Tuech JJ; Lehmann K; Mehta S; Glehen O; Marchal F
    BMC Surg; 2022 Jan; 22(1):1. PubMed ID: 34996419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Meta analysis of whether cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy can improve survival in patients with colorectal cancer peritoneal metastasis].
    Liu D; Wang H; Yuan ZX; Chen WW; Wu ZJ; Liu XX; Luo J; Chu LL; Li Y; Cai J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):256-263. PubMed ID: 34645170
    [No Abstract]   [Full Text] [Related]  

  • 13. Short and long-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal cancer peritoneal metastasis: Propensity score-matched comparison between laparoscopy vs. open approaches.
    Chang SC; Fingerhut A; Chen WT
    Surg Oncol; 2022 Aug; 43():101766. PubMed ID: 35430126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Laparoscopy in Patients With Peritoneal Carcinomatosis Is Safe and Does Not Delay Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy.
    Hanna DN; Ghani MO; Hermina A; Mina A; Bailey CE; Idrees K; Magge D
    Am Surg; 2022 Apr; 88(4):698-703. PubMed ID: 34732056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for small bowel neuroendocrine tumors with peritoneal metastasis.
    Hajjar R; Mercier F; Passot G; Pasquer A; Gelli M; Levine EA; Villeneuve L; Poncet G; Walter T; Glehen O
    Eur J Surg Oncol; 2022 Jul; 48(7):1626-1630. PubMed ID: 35418324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: a systematic review and meta-analysis.
    Li J; Wang AR; Chen XD; Zhang YX; Pan H; Li SQ
    World J Surg Oncol; 2022 Jun; 20(1):200. PubMed ID: 35701802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperthermic intraperitoneal chemotherapy (HIPEC) as adjuvant and therapeutic options for patients with advanced gastric cancer at high risk of recurrence or established peritoneal metastases: a single-centre experience.
    Allievi N; Bianco F; Pisano M; Montori G; Fugazzola P; Coccolini F; Lotti M; Mosconi S; Merelli B; Campanati L; Lucianetti A; Ansaloni L; Magnone S
    Updates Surg; 2023 Jan; 75(1):159-167. PubMed ID: 36371549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review.
    Auer RC; Sivajohanathan D; Biagi J; Conner J; Kennedy E; May T
    Eur J Cancer; 2020 Mar; 127():76-95. PubMed ID: 31986452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
    Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y
    Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.